Tyra Bioscience (TYRA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyra Biosciences, Inc. announced that the FDA has granted Rare Pediatric Disease Designation to their drug TYRA-300, a treatment for achondroplasia. This designation is for drugs addressing serious conditions affecting fewer than 200,000 people in the U.S., primarily children under 18. If TYRA-300’s New Drug Application is successful, Tyra may receive a Priority Review Voucher, which expedites future drug approvals. The company plans to submit an IND for a Phase 2 trial of TYRA-300 in the latter half of 2024.
For further insights into TYRA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.